Rational Design of Cancer Drug Combinations

Jiaxu Liu

doi:10.54254/2753-8818/2025.AU25018

Theoretical and Natural ScienceOpen access

Rational Design of Cancer Drug Combinations

Research Article

Open Access

Rational Design of Cancer Drug Combinations

Jiaxu Liu ^1*

¹ Asheville School, 360 Asheville School Rd, Asheville, NC 28806, USA

^*Corresponding author: liuaiden623@outlook.com

Published on 20 July 2025

TNS Vol.126

ISSN (Print): 2753-8826

ISSN (Online): 2753-8818

ISBN (Print): 978-1-80590-265-2

ISBN (Online): 978-1-80590-266-9

Download Cover

Abstract

Cancer, despite decades of focused research and treatment development, still stands as one of the most stubborn threats to human health. Common treatments such as surgery, radiation, chemotherapy are effective, but they often fall short. Side effects can be severe, and results vary from patient to patient. More recent strategies, like immunotherapy or targeted drugs, seem promising but don't work across the board. What this paper tries to do is look at an alternative—combining drugs in a way that zeroes in on how cancer cells work differently from normal ones. Tumors grow in ways they shouldn't,mess with metabolism, resist cell death, and even fool the immune system. That opens the door to some overlooked treatments—things that change how cancer cells make energy, or that ramp up oxidative stress. It even includes tools like DNA origami, which sounds strange but lets drugs be delivered more precisely. The point isn’tto find one cure, but to build smarter combinations that match the disease’s complexity and do less harm in the process.

Keywords:

cancer therapy, drug combinations, apoptosis, metabolism, immunotherapy

View PDF

References

[1]. Ahmad, F. B., Cisewski, J. A., & Anderson, R. N. (2024). Mortality in the United States—Provisional Data, 2023. MMWR. Morbidity and Mortality Weekly Report, 73(31), 173–178.

[2]. Patel, P., & Saikaley, A. (2019). Cyclin-dependent kinase inhibitors in cancer therapy. Current Oncology Reports, 21(10), 86.

[3]. Venerando, A., et al. (2024). Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments. Exploration of Drug Science, 2(1), 100–117.

[4]. Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033.

[5]. Wheaton, W. W., et al. (2014). Metformin inhibits mitochondrial complex I of cancer cells to reduce oxidative phosphorylation and ATP levels. Biochemical Journal, 462(3), 475–490.

[6]. Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in BRCA-deficient tumours. Science, 355(6330), 1152–1158.

[7]. Zhang, H., & Chen, J. (2022). Reinvigorating T cells in cancer: Combining immune checkpoint blockade with other therapies. Frontiers in Immunology, 13, 902–915.

[8]. Reilley, M. J., & Sears, R. C. (2019). Targeting AMPK for cancer prevention and treatment. Seminars in Cancer Biology, 57, 1–10.

[9]. Almeida, A., et al. (2018). Pyruvate kinase M2 and the balance of growth and energy in cancer. Molecular Cancer, 17, 150.

[10]. Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). NAD+ metabolism as a target for metabolic health and ageing. Nature Reviews Molecular Cell Biology, 19(4), 213–230.

[11]. Dong, Y., et al. (2020). β-Lapachone promotes tumor-selective cell death by NQO1-dependent ROS generation. Free Radical Biology and Medicine, 162, 594–604.

[12]. Cochemé, H. M., et al. (2012). A mitochondria-targeted mass spectrometry probe to detect superoxide production. Biochemical Journal, 444(3), 505–515.

[13]. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807–818.

[14]. Pirola, L., & Frojdo, S. (2008). Resveratrol: One molecule, many targets. IUBMB Life, 60(5), 323–332.

[15]. Shi, Y., Fan, S., & Wu, M. (2020). Berberine suppresses cancer cell proliferation by inhibiting fatty acid synthesis and metabolic reprogramming. Biochemical Pharmacology, 174, 113776.

[16]. Santoni, G., et al. (2020). Transient receptor potential channels in cancer therapy. Cancer Letters, 440-441, 116–122.

[17]. Mohri, K., et al. (2021). DNA origami nanostructures in drug delivery: A perspective for cancer therapy. Drug Target Review.

[18]. Takeuchi, O., & Akira, S. (2016). STING signalling and its role in innate immunity. Clinical and Experimental Immunology, 189(2), 119–126.

[19]. Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017). Indoleamine 2, 3-dioxygenase (IDO) pathway inhibition in cancer immunotherapy. Frontiers in Immunology, 8, 386.